mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex

Abstract excerpt

Between 1993 and 2003, through experiments involving Drosophila sp., cancer biologists identified the protein kinase known as the mammalian target of rapamycin, its pathway, and its relationship to the genes responsible for tuberous sclerosis. Thereafter, clinical research has resulted in regulatory approval of mTOR inhibitors for four distinct manifestations of the disease: giant cell astrocytoma,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Tuberous Sclerosis Complex Research